Circulating oxysterols and prognosis among women with a breast cancer diagnosis: results from the MARIE patient cohort

• Published in: BMC medicine 2023-11, Vol.21 (1), p.438-438, Article 438
• Main Authors: Decker, Nina Sophia, Johnson, Theron, Vey, Johannes A, Le Cornet, Charlotte, Behrens, Sabine, Obi, Nadia, Kaaks, Rudolf, Chang-Claude, Jenny, Fortner, Renée Turzanski
• Format: Article
• Language: English
• Subjects: Analysis; Biological markers; Biomarkers; Biosynthesis; Breast cancer; Breast Neoplasms - diagnosis; Cancer death; Cancer therapies; Cardiovascular death; Cardiovascular disease; Cardiovascular Diseases; Cholesterol; Cholesterol metabolism; Chronic illnesses; Coronary artery disease; Diagnosis; Endocrine therapy; Estrogens; Female; Health aspects; Health hazards; Health risks; Heart diseases; Humans; Investigations; Lanosterol; Lipid metabolism; Mass Spectrometry; Medical diagnosis; Medical prognosis; Medical records; Menstruation; Metabolism; Metabolites; Metastasis; Mortality; Oxysterols; Oxysterols - metabolism; Prognosis; Spectrometry; Statistical analysis; Statistical models; Survival; Women; Womens health
• ISSN: 1741-7015; 1741-7015
• DOI: 10.1186/s12916-023-03152-7

Breast cancer is the most commonly diagnosed cancer in women worldwide, and underlying mechanistic pathways associated with breast cancer-specific and non-breast cancer-related deaths are of importance. Emerging evidence suggests a role of oxysterols, derivates of cholesterol, in multiple chronic diseases including breast cancer and coronary artery diseases. However, associations between oxysterols and survival have been minimally studied in women diagnosed with breast cancer. In this large breast cancer patient cohort, we evaluated associations between a panel of circulating oxysterols and mortality and recurrence outcomes. Concentrations of 13 circulating oxysterols representing different pathways of cholesterol metabolism were quantified using liquid-chromatography mass-spectrometry. Associations between baseline levels of oxysterols and cause-specific mortality outcomes and recurrence following a breast cancer diagnosis were assessed in 2282 women from the MARIE study over a median follow-up time of 11 years. We calculated hazard ratios (HR) and 95% confidence intervals (CI) using multivariable Cox proportional hazard models and competing risks models. We observed no associations for circulating oxysterols and breast cancer-specific outcomes. Higher levels of six oxysterols were associated with an increased risk of cardiovascular disease death, including 24S-hydroxycholesterol (alternative bile acid pathway, HR  = 1.73 (1.02, 2.93)), lanosterol (cholesterol biosynthesis pathway, HR  = 1.95 (1.34, 2.83)), 7-ketocholesterol (HR  = 1.26 (1.03, 1.55)), 5α,6α-epoxycholesterol (HR  = 1.34 (1.02-1.77)), and 5a,6β-dihydroxycholestanol (HR  = 1.34 (1.03, 1.76)). After adjusting for multiple comparisons, none of the associations were statistically significant. We provide first evidence on a range of circulating oxysterols and mortality following a breast cancer diagnosis, contributing to a better understanding of associations between different pathways of cholesterol metabolism and prognosis in women with a breast cancer diagnosis. The findings of this study suggest circulating oxysterols may be associated with cardiovascular mortality among women diagnosed with breast cancer. Further studies are needed to evaluate these oxysterols as potential markers of risk for cardiovascular mortality among women with a breast cancer diagnosis as well as their clinical potential.